Twist Bioscience financials
$186.13+3.64%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Sep 30 | FY24 Sep 30 | FY23 Sep 30 | FY22 Sep 30 | FY21 Sep 30 | FY20 Sep 30 | FY19 Sep 30 |
|---|---|---|---|---|---|---|---|
| Revenue | $376.6M | $313.0M | $245.1M | $203.6M | $132.3M | $90.1M | $54.4M |
| Gross profit | $191.0M | $133.3M | $89.7M | $84.2M | $51.7M | $28.7M | $7.0M |
| Gross margin | 50.7% | 42.6% | 36.6% | 41.4% | 39.1% | 31.8% | 12.8% |
| Operating income | -$136.3M | -$220.8M | -$217.2M | -$230.2M | -$152.7M | -$140.1M | -$108.8M |
| Net income | -$77.7M | -$208.7M | -$204.6M | -$217.9M | -$152.1M | -$139.9M | -$107.7M |
| Net margin | −20.6% | −66.7% | −83.5% | −107.0% | −114.9% | −155.3% | −198.0% |
| Diluted EPS | $-1.30 | $-3.60 | $-3.60 | $-4.04 | $-3.15 | $-3.57 | $-3.92 |
| EBITDA | -$111.4M | -$144.5M | -$177.6M | -$218.3M | -$143.5M | -$110.9M | -$102.7M |
| Operating cash flow | -$47.6M | -$64.1M | -$142.5M | -$124.4M | -$112.2M | -$142.3M | -$87.9M |
| Free cash flow | -$75.6M | -$69.2M | -$170.3M | -$226.2M | -$139.3M | -$152.1M | -$102.7M |
| Diluted shares | 59.8M | 58.0M | 56.9M | 53.9M | 48.3M | 39.2M | 27.5M |
Balance sheet
| Period end | Sep 30 | Sep 30 | Sep 30 | Sep 30 | Sep 30 | Sep 30 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $183.0M | $226.3M | $286.5M | $378.7M | $465.8M | $93.7M |
| Short-term investments | $49.4M | $50.1M | $49.9M | $126.3M | $12.0M | $196.3M |
| Total debt | $15.0M | $0.00 | $0.00 | $0.00 | $1.6M | $4.7M |
| Total assets | $641.9M | $614.3M | $776.4M | $961.4M | $702.1M | $398.9M |
| Total liabilities | $168.9M | $141.6M | $153.0M | $172.0M | $121.3M | $62.6M |
| Shareholders' equity | $473.0M | $472.7M | $623.4M | $789.4M | $580.8M | $336.3M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology